Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharmaceuticals Limited is engaged in the marketing and distributing of finished formulations of pharmaceutical drugs.[1]
- Market Cap ₹ 1,185 Cr.
- Current Price ₹ 2,011
- High / Low ₹ 2,300 / 758
- Stock P/E 55.0
- Book Value ₹ 147
- Dividend Yield 0.07 %
- ROCE %
- ROE %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 1.05% over last quarter.
Cons
- Stock is trading at 13.9 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| 212 | |
| 185 | |
| Operating Profit | 28 |
| OPM % | 13% |
| 5 | |
| Interest | 0 |
| Depreciation | 1 |
| Profit before tax | 32 |
| Tax % | 18% |
| 26 | |
| EPS in Rs | 36.51 |
| Dividend Payout % | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 109% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| Equity Capital | |
| Reserves | |
| Total Liabilities | |
| CWIP | |
| Investments | |
| Total Assets |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| 4 | |
| -9 | |
| 24 | |
| Net Cash Flow | 19 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | |
|---|---|
| Debtor Days | |
| Inventory Days | |
| Days Payable | |
| Cash Conversion Cycle | |
| Working Capital Days | |
| ROCE % |
Documents
Announcements
-
Updates
19 June 2024 - Remus Pharmaceuticals Limited has informed regarding 'Receipt of Trading Approval for Bonus Equity Shares'.
-
Alteration Of Capital and Fund Raising-XBRL
10 June 2024 - REMUS PHARMACEUTICALS LIMITED has informed regarding Allotment of Securities
-
Allotment of Securities
10 June 2024 - Remus Pharmaceuticals Limited has informed regarding allotment of 4419000 equity shares pursuant to Bonus at its meeting held on Jun 10, 2024
-
Updates
30 May 2024 - Remus Pharmaceuticals Limited has informed regarding 'Intimation of receipt of In-principle Approval for Bonus Issue'.
-
Disclosure under SEBI Takeover Regulations
24 May 2024 - Arpit Deepakkumar Shah has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, …
Business Segments
A) APIs (84.5% of FY22 revenue)[1] Co has 54 products in this segment
B) Finished Pharmaceutical Formulations(15.5% of FY22 revenue)[1]